ENTO - צמיחת הכנסות ב-12 חודשים נגררים enterothera.com

לוגו של חברה ציבורית Entero Therapeutics Inc. (ENTO)

Entero Therapeutics, Inc. (ENTO) develops enzyme-based treatments to combat celiac disease, establishing a comprehensive therapy system for digestive pathologies. However, the lack of recurring revenue and the costs associated with clinical trials are creating a liquidity deficit. The relative change in trailing twelve-month revenue compared to the same period last year confirms these data, with the current level standing at 0.00, reflecting the reaction of commercial volumes to external market shifts.

ENTO - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים Entero Therapeutics בטווח 23.11.2025 - 01.12.2025

Entero Therapeutics - פילוחים אנליטיים ומדדי מפתח (ENTO)

- מחיר נוכחי ושווי מניות חזוי:
אנליטיקה מסכמת של החברה:enterothera.com
פריט של המותג enterothera.com

Entero Therapeutics, Inc. (ENTO) focuses on developing innovative therapies for patients with gastrointestinal pathologies, making the annual trend of sales revenue over four quarters a key indicator of its asset commercialization. This metric measures the market consensus of the value of goods sold over a rolling year on a daily basis, allowing investors to strip away accounting distortions and objectively assess the real demand for the company's drugs.